Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

rage us as we proceed expeditiously through our ongoing Phase 2 program."

Phase 1b Clinical Trial Design

This 14 day randomized, double-blind, placebo-controlled, sequential-group study of ascending multiple doses enrolled subjects with chronic HCV infection who were naive to treatment. Subjects were enrolled in sequential, ascending dose cohorts with a target of 16 subjects (12 subjects receiving HCV-796 BID and 4 receiving placebo in each cohort). The first cohorts assessed the effect of HCV-796 as monotherapy compared to placebo (data from which were released on November 10, 2005). Subsequent cohorts were comprised of subjects who received peg-IFN (PEG-Intron; 1.5 ug/kg/dose) on days -1 and 7 in combination with either placebo or HCV-796 (100 mg, 250 mg, 500 mg or 1000 mg) every 12 hours, from days 1 to 14.

Antiviral Activity Results

Data are available through treatment day 14 from subjects in four combination treatment groups (n= 10 to 12 subjects per group) and on 19 subjects who received peg-IFN alone.

-- For genotype 1, mean reduction from baseline ranged from 1.5 to 2.3 log10 on day 7 and from 2.6 to 3.2 log10 on day 14 in the combination therapy groups compared to 0.9 log10 on day 7 and 1.3 log10 on day 14 for peg-IFN alone.

-- For non-genotype 1, mean reduction from baseline ranged from 2.8 to 3.5 log10 on day 7 and from 3.5 to 4.8 log10 on day 14 in the combination therapy groups compared to 1.5 log10 on day 7 and 2.6 log10 on day 14 for peg-IFN alone.

-- Viral reduction greater or equal to 2.0 log10 at day 14 was achieved in 70 to 92 percent of subjects in all combination groups compared to 40 percent on peg-IFN alone.

-- At day 14, 30 to 33 percent of patients in the combination groups receiving greater than or equal to 250 mg BID of HCV-796 achieved viral levels below the quantification limit of 50 IU/mL HCV RNA.

Safety and Tolerability Results

A safety review of HCV-796 in combinati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:4/21/2015)... 2015 Oxfordshire ... more than doubled its overseas sales in just 4 ... winning the Queen,s Award for Enterprise, for Outstanding Achievement ... first HealthScience Communications consultancy, helping its clients bring new ... Having more than doubled its exports in just 4 ...
(Date:4/21/2015)... Cardiologists at Henry Ford Hospital have implanted a device that ... heartbeat. With only handful of hospitals in the ... to add another option to its arsenal of tools for ... to pump. "This is a first in ... at a non-clinical trial site," says cardiologist Claudio Schuger ...
(Date:4/21/2015)...  St. Vincent Healthcare is raising the bar ... strict disinfection routines, St. Vincent Healthcare is now also ... germs, like Ebola, methicillin-resistant Staphylococcus aureus ... patients during their hospital stay. ... http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Local Consultancy 2Queen's Award Crowns Achievements of Local Consultancy 3Queen's Award Crowns Achievements of Local Consultancy 4Queen's Award Crowns Achievements of Local Consultancy 5Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3
... Demonstrates Increased Dermal Penetration of TPM/Lidocaine Compared to Topical ... MELBOURNE, Australia, Dec. 8 Phosphagenics Limited ("Phosphagenics") (ASX: POH; ... phase 1 clinical trial that examined the ability of ... the pain relief drug, lidocaine, safely into humans. The ...
... first vaccine candidate for the prevention of RSV , ... Novavax, Inc. (Nasdaq: NVAX ) announced today that ... University of Massachusetts Medical School , will be presenting ... for the prevention of respiratory syncytial virus ("RSV") at the ...
Cached Medicine Technology:Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine 2Positive Phase 1 Clinical Trial Results for Transdermal Lidocaine 3Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate 2
(Date:4/21/2015)... 21, 2015 On April 2, 2015, ... to Achieve Kylie Jenner Lips With Disastrous ... injured themselves while attempting an at-home lip augmentation ... is that creating an airlock around one’s mouth for ... plump and achieve Kylie Jenner’s now famous pout. (see: ...
(Date:4/21/2015)... April 21, 2015 “ ZeroWire ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... how ZeroWire is a security system and lifestyle management ... there were over 2 million burglaries in 2010. It ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... Wireless Analytics, LLC , a pioneering ... the Boston Business Journal as the 25th fastest-growing private ... a recent event celebrating the 2015 Pacesetters, the ... companies in Massachusetts. , Wireless Analytics was ranked among ... the fastest revenue growth from 2011 through 2014. ...
(Date:4/21/2015)... 2015 The report “Dermatitis ... analysis on the therapeutic development for Dermatitis. ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
Breaking Medicine News(10 mins):Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... - Health Professionals Calling for Further Guidance From Department ... plastic baby bottles has,been making headlines in North America, ... that 92%(1) of mums are not aware of the ... Us are phasing out,all baby bottles containing Bisphenol-A and ...
... A new report, funded and released by,Avalere Health, showed ... its,CY 2008 Part D Formulary Reference File. In response, ... Medicare offerings in 2008,resulting in significantly smaller Part D ... driven in part to remove hundreds of prescription,drugs that ...
... A large genetic study in mice has identified hundreds of ... DNA of more than 500 lymphomas to find the cancer ... mutations in total, which together implicate almost 350 regions in ... correspond to genes known to be involved in human cancers ...
... focuses on solving real-world problems ... in radiology, ... in radiology and medical image and information management solutions,today announced that its ... at the SIIM 2008,Annual Meeting in Seattle, WA, from May 15 to ...
... Life and Casualty,Company, a national life and health insurer, ... Alzheimer,s Association Rita Hayworth Gala for,their support of the ... "Bankers Life has organized Forget Me Not Days over ... 2003 to support both national and,local efforts," said Harry ...
... the use of pacemakers,implantable cardioverter-defibrillators (ICDs) and ... May 15 The American College,of Cardiology ... Heart Rhythm,Society (HRS) have jointly released updated ... for Device-Based Therapy of,Cardiac Rhythm Abnormalities are ...
Cached Medicine News:Health News:Bounty Poll Reveals British Mums in the Dark Over Bisphenol-A in Baby Bottles 2Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 2Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 3Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 4Health News:Connecting cancer genes 2Health News:AMICAS Focuses on the Future of Radiology IT at SIIM 2008 2Health News:AMICAS Focuses on the Future of Radiology IT at SIIM 2008 3Health News:Bankers Life and Casualty Company Named Corporate Honoree at Alzheimer's Association Chicago Rita Hayworth Gala 2Health News:The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines 2Health News:The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines 3Health News:The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines 4
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Anterior Chamber Needle, 27 g., 5 mm from bend to tip. Overall length 22 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
Medicine Products: